Cognition Net Invested Capital from 2010 to 2024

CGTX Stock  USD 0.41  0.02  4.65%   
Cognition Therapeutics Net Invested Capital yearly trend continues to be fairly stable with very little volatility. Net Invested Capital is likely to outpace its year average in 2024. Net Invested Capital is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. View All Fundamentals
 
Net Invested Capital  
First Reported
2010-12-31
Previous Quarter
25 M
Current Value
26.3 M
Quarterly Volatility
40.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cognition Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cognition Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 91.2 K, Interest Expense of 25.6 K or Selling General Administrative of 9.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.38. Cognition financial statements analysis is a perfect complement when working with Cognition Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cognition Therapeutics Correlation against competitors.
For more information on how to buy Cognition Stock please use our How to Invest in Cognition Therapeutics guide.

Latest Cognition Therapeutics' Net Invested Capital Growth Pattern

Below is the plot of the Net Invested Capital of Cognition Therapeutics over the last few years. It is the total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents. Cognition Therapeutics' Net Invested Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cognition Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Invested Capital10 Years Trend
Slightly volatile
   Net Invested Capital   
       Timeline  

Cognition Net Invested Capital Regression Statistics

Arithmetic Mean(28,475,940)
Coefficient Of Variation(142.53)
Mean Deviation34,312,888
Median(51,525,000)
Standard Deviation40,587,643
Sample Variance1647.4T
Range106.6M
R-Value0.73
Mean Square Error817.9T
R-Squared0.54
Significance0
Slope6,662,951
Total Sum of Squares23063T

Cognition Net Invested Capital History

202426.3 M
202325 M
202240.9 M
202151.3 M
2020-55.3 M

About Cognition Therapeutics Financial Statements

Cognition Therapeutics investors use historical fundamental indicators, such as Cognition Therapeutics' Net Invested Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cognition Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Invested Capital25 M26.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cognition Stock Analysis

When running Cognition Therapeutics' price analysis, check to measure Cognition Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cognition Therapeutics is operating at the current time. Most of Cognition Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cognition Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cognition Therapeutics' price. Additionally, you may evaluate how the addition of Cognition Therapeutics to your portfolios can decrease your overall portfolio volatility.